Abstract:BACKGROUND:Conventional formulation of levofloxacin is rapidly and completely metabolized after administration. Fortunately, nanoparticle provides a new way to solve this problem. OBJECTIVE:To prepare a levofloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticle that can reduce administration frequency, maintain a stable and effective plasma concentration, and also can be combined with tissue-engineered scaffold materials. METHODS:Levofloxacin-loaded PLGA nanoparticles were prepared by emulsion solvent evaporation method. Twenty-four rabbits were taken to investigate the effect of nanoparticle formulation on the pharmacokinetics of levofloxacin and randomized into three groups (n=8 per group): general formulation group received an injection of levofloxacin (20 mg/kg)via ear vein; non-loaded nanoparticle group received an injection of blank nanoparticles; and levofloxaxin-loaded nanoparticle group received an injection of the corresponding levofloxacin-loaded nanoparticles. At different times, blood samples were collected to analyze the drug concentration of levofloxaxin. The antimicrobial activity of the levofloxacin-loaded nanoparticle was evaluated based on the rabbit model of Escherichia coli-induced urinary tract infection. Forty-five New Zealand white rabbits were used to establish urinary tract infection models and randomly divided into three groups (n=15 per group). In negative control group, rabbits received only an injection of normal salinevia ear vein. In conventional formulation group, rabbits received an injection of levofloxacin (20 mg/kg). In nanoparticle group, rabbits received an injection of the corresponding levofloxacin nanoparticles. Subsequently, blood samples were obtained, and white blood cell (WBC) count and neutrophil percentage was tested; at the same time, the middle segment morning urine was collected to detect bacteriuria and urine WBC positive rates. At 9 days, the histopathologic analysis of the bladder mucosa was done. RESULTS AND CONCLUSION:(1)In vivo the pharmacokinetics: Compared with the conventional formulation group, the ideal levofloxacin-loaded PLGA nanoparticles prepared under optimal conditions significantly reduced the fluctuations in plasma concentration and frequency of administration. (2) Antimicrobial activity:Escherichia coli-induced urinary tract infection was gradualy in control in the conventional formulation group and levofloxacin-loaded PLGA nanoparticle group, and basically cured at 9 days after injection. In addition, the number of cured patients was basically higher in the levofloxacin-loaded PLGA nanoparticle group than the conventional formulation group at the same time point, but there was a significant difference between the two groups only at 5 days after treatment. It can be concluded that levofloxacin-PLGA nanoparticles provide a well-sustained delivery system for treatment or prevention of urinary tract infections and provide a foundation for further investigations on tissue-engineered urethral reconstruction.

Prolonged systemic delivery of antibacterial agent levofloxacin using liposomes

Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation.

Preparation and characterization of PEG coating levofloxacin-liposomes

Preparation and Physicochemical Characterization of Levofloxacin-Loaded Poly(lactic-Co-glycolic Acid) Nanoparticles

In Vitro and in Vivo Evaluation of Levofloxacin Sustained-Release Capsules.

Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation

Colon-target drug delivery of levofloxacin microshperes in rats

Study on Colon-Specific Delivery of Carboxymethylchitosan Microspheres Containing Levofloxacin

Percutaneous penetration of levofloxacin lactate liposome gel

Preparation and Controlled Release of Colon-Targeted Carboxymethylchitosan Microspheres Containing Levofloxacin:An in Vivo Study

Study on Encapsulation Efficiency and In vitro Release Profile of Levofloxacin Hydrochloride Liposome

The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B

Enhanced Bioavailability of the Poorly Water-Soluble Drug Fenofibrate by Using Liposomes Containing a Bile Salt

Optimized Preparation of Levofloxacin Loaded Polymeric Nanoparticles

Chitosan-coated liposome with lysozyme-responsive properties for on-demand release of levofloxacin

Improved Antitumor Efficacy and Reduced Toxicity of Liposomes Containing Bufadienolides

Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections

The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate

Poly-D, L-lactide and levofloxacin-blended beads: A sustained local releasing system to treat osteomyelitis

Permeability and Concentration of Levofloxacin in Epithelial Lining Fluid in Patients with Lower Respiratory Tract Infections

Multivesicular Liposome Formulation for the Sustained Delivery of Breviscapine.